Here is Matt Lowdon‘s weekly deal round up of news across Medical Devices and Biotechnology. The headlines cover gene therapy manufacturing, BCI technology, neurodegeneration, and more.
🔔 After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more than $158 million to boost its production and commercial push.
🔔 UK-based Cellular Origins has raised $40m to scale global CGT manufacturing with robotic automation, boosting access to cell therapies and enabling commercial growth.
🔔 Moderna has tapped Swedish long-acting drug formulation company Nanexa AB to improve the delivery of up to five injectable therapies with $3m upfront, and a potential $500m overall.
🔔 Cologne-based DISCO Pharmaceuticals GmbH has closed its seed financing at €36m. The company will use the proceeds to advance its surfaceome-mapping platform, developing bispecific ADCs and T-Cell Engagers for hard-to-treat cancers.
🔔 Subsense Inc. announced that it added $10 million in new capital to support its nanoparticle-based brain-computer interface (BCI) platform.
🔔 Spanish Tetraneuron secures financing to advance its E2F4DN-based Alzheimer’s gene therapy, restoring neuronal homeostasis and halting disease progression in Europe.
🔔 Chinese biotech D3 Bio, led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans.
🔔 The British Business Bank has invested £10.5m in EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, as part of a $33 million Series A financing round.
🔔 SanegeneBio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and broaden development across metabolic, cardiovascular and autoimmune diseases.
🔔 AstraZeneca has joined a near-$100 million series A and A+ financing round for Syneron Tech, a biotechnology startup focused on macrocyclic peptide therapies for oncology and chronic diseases.